Day: June 16, 2021

Nexus REIT Announces Acquisition Update and June Distribution

Nexus REIT Announces Acquisition Update and June Distribution

TORONTO and MONTREAL, June 16, 2021 (GLOBE NEWSWIRE) — Nexus Real Estate Investment Trust (the “REIT”) (TSX: NXR.UN) announced today an acquisition update, the June distribution, and the expected sale of a retail property located in Beamsville, Ontario. Industrial Acquisitions Completed to Date in 2021 March 1, 2021: acquired two industrial buildings in Edmonton, Alberta with 108,156 square feet of gross leasable area (GLA) for $14MM. The buildings are fully leased to non-oil and gas tenants. The REIT issued $7.0MM in Class B LP units to the vendor at a price of $8.20 per unit. The purchase price represented an approximately 8% going in capitalization rate. April 1, 2021: completed the $103.5MM acquisition of six industrial properties in London, Ontario with 1,191,184 square feet of GLA, representing a 6% going-in...

Continue reading

C4 Therapeutics Announces Pricing of Public Offering

C4 Therapeutics Announces Pricing of Public Offering

WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share. All of the shares of common stock in the offering will be offered by C4T. In addition, C4T granted the underwriters a 30-day option to purchase up to 637,500 additional shares of common stock at the public offering price, less the underwriting discount and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by C4T, are expected to be approximately...

Continue reading

Preferred Bank Announces Quarterly Cash Dividend

Preferred Bank Announces Quarterly Cash Dividend

LOS ANGELES, June 16, 2021 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the largest independent commercial banks in California, today reported that the Board of Directors has declared a quarterly cash dividend of $0.38 per share. The dividend is payable on July 21, 2021 to holders of record on July 7, 2021. About Preferred Bank Preferred Bank (the “Bank”) is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through eleven full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia,...

Continue reading

Educational Development Corporation Announces Record Fiscal First Quarter Estimated Net Revenues, Earnings and Active Sales Consultants in the Company’s UBAM Division

Educational Development Corporation Announces Record Fiscal First Quarter Estimated Net Revenues, Earnings and Active Sales Consultants in the Company’s UBAM Division

TULSA, Okla., June 16, 2021 (GLOBE NEWSWIRE) — Educational Development Corporation (“EDC”, or the “Company”) (NASDAQ: EDUC) (http://www.edcpub.com) reports that the Company has estimated net revenues in fiscal first quarter 2022 totaling approximately $40.8 million. This represents an increase of $2.5 million, or 6.5%, from net revenues achieved in fiscal first quarter 2021 of $38.3 million.   The Company estimates earning per share for the quarter between $0.38 and $0.41, which is an increase over the earnings of $0.23 per share reported for the first quarter of fiscal 2021. The Company’s Usborne Books & More (UBAM) division averaged approximately 55,100 active consultants during the first quarter, an increase of 66% over 33,100 average active consultants reported for the first quarter last year. Per Randall White, Chief...

Continue reading

Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

Transaction Expected to Close in the 2021 Third Quarter Tel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) — Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus (“Proxy Statement”), with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. Quoin is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin’s leadership team is made up of industry veterans, with extensive relevant executive experience and proven records of recent success in the pharmaceutical industry. The transaction is currently expected to close in the 2021 third...

Continue reading

Grom Social Enterprises, Inc. Announces Nasdaq Uplisting and Pricing of $10.0 Million Public Offering

Grom Social Enterprises, Inc. Announces Nasdaq Uplisting and Pricing of $10.0 Million Public Offering

BOCA RATON, June 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Grom Social Enterprises, Inc. (NASDAQ: GROM) (“Grom”, the “Company”) a social media platform and original content provider for children under the age of 13, today announced the pricing of an underwritten public offering of 2,409,639 units at a public offering price of $4.15 per unit for aggregate gross proceeds of approximately $10.0 million prior to deducting underwriting discounts, commissions, and other offering expenses. Each unit is comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable for one share of common stock at an exercise price of $4.565 per share and will expire five years from issuance. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional...

Continue reading

CenterPoint Energy, Inc. to Host Webcast of Second Quarter 2021 Earnings Conference Call

CenterPoint Energy, Inc. to Host Webcast of Second Quarter 2021 Earnings Conference Call

Houston, TX, June 16, 2021 (GLOBE NEWSWIRE) —   Date:  August 5, 2021 Time:  7:00 a.m. Central time or 8:00 a.m. Eastern time Listen via internet:  http://investors.centerpointenergy.com/ Click “Investors”, and click the link “CenterPoint Energy, Inc. Second Quarter 2021 Earnings Conference call Webcast” As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Arkansas, Indiana, Louisiana, Minnesota, Mississippi, Ohio, Oklahoma and Texas. As of March 31, 2021, the company owned approximately $36 billion in assets and also owned 53.7 percent of the common units representing...

Continue reading

Suncor Energy and Terra Nova co-owners reach Agreement in Principle on Terra Nova

Suncor Energy and Terra Nova co-owners reach Agreement in Principle on Terra Nova

CALGARY, Alberta, June 16, 2021 (GLOBE NEWSWIRE) — Suncor today advised that the co-owners of the Terra Nova Floating, Production, Storage and Offloading (FPSO) facility and associated Terra Nova Field (“Terra Nova” or “the project”) have reached an agreement in principle to restructure the project ownership and provide short-term funding towards continuing the development of the Asset Life Extension Project, with the intent to move to a sanction decision in the Fall. A subset of owners will increase their ownership of the project for consideration payable from the other owners. Suncor’s ownership will increase to 48% from approximately 38%. The agreement is subject to finalized terms and approval from all Parties, including board of director approval where appropriate, and is contingent upon the previously disclosed royalty and...

Continue reading

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG) Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date Breda, the Netherlands —Jun. 16, 2021— argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Efgartigimod is currently under review with the U.S. Food and Drug Administration (FDA) for the treatment of gMG with a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2021, and if approved, would...

Continue reading

Euro Manganese Announces CEO Succession Plan

Euro Manganese Announces CEO Succession Plan

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF) (“EMN” or the “Company“) today announced that it will begin implementation of a CEO succession plan. A search will now begin for a new Chief Executive Officer to carry the Company through its next stage of development, as it transitions from a development company to an operating company. Marco Romero, the founder of the Company and its current CEO, will remain in the CEO position until a successor is identified and appointed. Marco Romero said, “I have been looking for the right opportunity to make way for a new CEO for some time and have been working closely with the Board to set the stage for a transition. This current phase, where we are busy completing our...

Continue reading